{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:55:16Z","timestamp":1777434916765,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Industry-Academia collaboration"},{"name":"Alkermes Inc"},{"name":"Science Foundation Ireland and Alkermes Inc","award":["14\/SPP\/B3051"],"award-info":[{"award-number":["14\/SPP\/B3051"]}]},{"name":"Alkermes Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.neuropharm.2018.12.012","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T12:28:20Z","timestamp":1544704100000},"page":"327-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats"],"prefix":"10.1016","volume":"146","author":[{"given":"Nikita N.","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehnaz","family":"Ferdousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Deaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-621X","authenticated-orcid":false,"given":"David P.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-9397","authenticated-orcid":false,"given":"Michelle","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.12.012_bib1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/0269881115586937","article-title":"Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice","volume":"29","author":"Almatroudi","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1476-5381.1972.tb06866.x","article-title":"Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment","volume":"46","author":"Babbini","year":"1972","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neulet.2004.03.041","article-title":"Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice","volume":"363","author":"Berrocoso","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.118.249839","article-title":"In vitro pharmacological characterization of bupernorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder","volume":"367","author":"Bidlack","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0893-133X(01)00413-4","article-title":"Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats","volume":"26","author":"Broom","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbr.2014.10.014","article-title":"Antidepressant-like effects of buprenorphine in rats are strain dependent","volume":"278","author":"Browne","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.physbeh.2016.08.031","article-title":"Sex differences and similarities in depressive- and anxiety-like behaviour in the Wistar-Kyoto rat","volume":"167","author":"Burke","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/gbb.12080","article-title":"Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala","volume":"12","author":"Burke","year":"2013","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.neuroscience.2010.10.030","article-title":"Enhanced nociceptive responding in two rat models of depression is associated with alterations in monoamine levels in discrete brain regions","volume":"171","author":"Burke","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0006-3223(96)00158-8","article-title":"Buprenorphine for depression: the un-adoptable orphan","volume":"39","author":"Callaway","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/npp.2009.183","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats","volume":"35","author":"Carr","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib13","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/npp.2013.117","article-title":"Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence","volume":"38","author":"Chaijale","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0376-8716(98)00192-6","article-title":"Plasma concentrations of buprenorphine 24 to 72 hours after dosing","volume":"55","author":"Chawarski","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brainres.2004.06.052","article-title":"A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression","volume":"1021","author":"De La Garza","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib16","first-page":"S435","article-title":"Effects of buprenorphine and ALKS 33, alone and in combination, on monoamine release within the nucleus accumbens shell and medial prefrontal cortex of male wistar rats","author":"Deaver","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0166-4328(96)00067-8","article-title":"Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth","volume":"73","author":"Detke","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02245592","article-title":"Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants","volume":"121","author":"Detke","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0022-3565(25)39324-9","article-title":"Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies","volume":"266","author":"Devine","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00432028","article-title":"Influence of naloxone on antidepressant drug effects in the forced swimming test in mice","volume":"84","author":"Devoize","year":"1984","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00001756-200002280-00038","article-title":"Sleep in the Wistar-Kyoto rat, a putative genetic animal model for depression","volume":"11","author":"Dugovic","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib22","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.pnpbp.2007.06.023","article-title":"Development of a home cage locomotor tracking system capable of detecting the stimulant and sedative properties of drugs in rats","volume":"31","author":"Dunne","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib23","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/syn.20122","article-title":"Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA\/2J and C57BL\/6J mice","volume":"56","author":"Fadda","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0006-8993(95)00333-L","article-title":"Increased density of mu-opioid receptors in the postmortem brain of suicide victims","volume":"682","author":"Gabilondo","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.2042-7158.1978.tb13342.x","article-title":"Opiate-receptor mediated changes in monoamine synthesis in rat brain","volume":"30","author":"Garcia-Sevilla","year":"1978","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/syn.1088","article-title":"Plasmalemmal mu-opioid receptor distribution mainly in nondopaminergic neurons in the rat ventral tegmental area","volume":"41","author":"Garzon","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0006-8993(90)91301-V","article-title":"Regionally selective increases in mu opioid receptor density in the brains of suicide victims","volume":"530","author":"Gross-Isseroff","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib29","first-page":"18","article-title":"An evaluation of analgesic regimens for abdominal surgery in mice","volume":"39","author":"Hayes","year":"2000","journal-title":"Contemp. Top. Lab. Anim. Sci."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib30","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib31","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","article-title":"Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults","volume":"75","author":"Karp","year":"2014","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuroscience.2011.09.032","article-title":"Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor","volume":"204","author":"Kerr","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0740-5472(90)90035-O","article-title":"Depressive symptoms during buprenorphine treatment of opioid abusers","volume":"7","author":"Kosten","year":"1990","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib35","first-page":"37","article-title":"The ambulation-increasing effect of buprenorphine in mice: comparison with the effect of morphine","volume":"26","author":"Kuribara","year":"1991","journal-title":"Arukoru Kenkyu Yakubutsu Izon"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-2999(97)01276-4","article-title":"Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants?","volume":"337","author":"Lahmame","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib37","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","article-title":"Buprenorphine has potent kappa opioid receptor antagonist activity","volume":"26","author":"Leander","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.drugalcdep.2006.03.017","article-title":"Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse","volume":"85","author":"Lelong-Boulouard","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1258\/002367792780740558","article-title":"The effects of buprenorphine, nalbuphine and butorphanol alone or following halothane anaesthesia on food and water consumption and locomotor movement in rats","volume":"26","author":"Liles","year":"1992","journal-title":"Lab. Anim"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0893-133X(99)00100-1","article-title":"Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test","volume":"22","author":"Lopez-Rubalcava","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib41","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib43","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.neuropharm.2007.01.005","article-title":"The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference","volume":"52","author":"Marquez","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","article-title":"Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy","volume":"28","author":"Nyhuis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0031-9384(89)90203-5","article-title":"Stress ulcer susceptibility and depression in Wistar Kyoto (WKY) rats","volume":"46","author":"Pare","year":"1989","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0361-9230(00)00362-2","article-title":"Investigatory behavior of a novel conspecific by wistar Kyoto, wistar and sprague-dawley rats","volume":"53","author":"Pare","year":"2000","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0928-4257(93)90010-Q","article-title":"Depressive behavior and stress ulcer in Wistar Kyoto rats","volume":"87","author":"Pare","year":"1993","journal-title":"J. Physiol. Paris"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib48","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/sj.npp.1301100","article-title":"Identifying genes in monoamine nuclei that may determine stress vulnerability and depressive behavior in Wistar-Kyoto rats","volume":"31","author":"Pearson","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s002130050555","article-title":"Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test","volume":"136","author":"Reneric","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0306-4530(01)00052-X","article-title":"Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat","volume":"27","author":"Rittenhouse","year":"2002","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2016.10.050","article-title":"A role for the mu opioid receptor in the antidepressant effects of buprenorphine","volume":"319","author":"Robinson","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib52","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/026988110401800305","article-title":"Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates","volume":"18","author":"Rojas-Corrales","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1098-2396(199911)34:2<83::AID-SYN1>3.0.CO;2-S","article-title":"Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu\/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay","volume":"34","author":"Romero","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0165-1781(90)90082-G","article-title":"Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data","volume":"32","author":"Scarone","year":"1990","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/JCP.0000000000000320","article-title":"Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent mu-receptor antagonist","volume":"35","author":"Shram","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/SAR.S45585","article-title":"New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone","volume":"6","author":"Soyka","year":"2015","journal-title":"Subst. Abuse Rehabil."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.psyneuen.2007.03.012","article-title":"Plasma corticosterone, dexamethasone (DEX) suppression and DEX\/CRH tests in a rat model of genetic vulnerability to depression","volume":"32","author":"Steimer","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2190\/PM.47.2.g","article-title":"The anti-suicidal potential of buprenorphine: a case report","volume":"47","author":"Striebel","year":"2014","journal-title":"Int. J. Psychiatr. Med."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib59","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(95)00154-B","article-title":"Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain","volume":"68","author":"Tao","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0278-5846(02)00308-1","article-title":"Strain-dependent modification of behavior following antidepressant treatment","volume":"27","author":"Tejani-Butt","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-3565(25)20595-X","article-title":"Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation","volume":"232","author":"Tempel","year":"1985","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10550880802122646","article-title":"Psychotherapeutic benefits of opioid agonist therapy","volume":"27","author":"Tenore","year":"2008","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neuropharm.2018.12.012_bib63","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2012.03.052","article-title":"Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA\/NMDA receptor density ratio in female Wistar-Kyoto rats","volume":"213","author":"Tizabi","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib65","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","article-title":"Syntheses of novel high affinity ligands for opioid receptors","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bmcl.2008.10.134","article-title":"Syntheses and opioid receptor binding properties of carboxamido-substituted opioids","volume":"19","author":"Wentland","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2018.12.012_bib67","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.bmcl.2005.02.032","article-title":"Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone","volume":"15","author":"Wentland","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818309092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818309092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:55:56Z","timestamp":1758437756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818309092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":67,"alternative-id":["S0028390818309092"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.12.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}